Characteristics | Placebo | MF |
Subjects | 70 | 70 |
Female | 52 (74) | 47 (67) |
Age at entry yrs | | |
Mean | 47±11 | 45±12 |
Range | 20–64 | 21–67 |
Race | | |
Caucasian | 66 (94) | 66 (94) |
Other | 4 (6) | 4 (6) |
FEV1 L | | |
Mean | 3.19±0.81 | 3.13 ±0.78 |
Range | 1.68–5.41 | 1.84–5.30 |
FEV1 % pred | | |
Mean | 104.2±15.5 | 103.5±13.2 |
Range | 81–147 | 75–133# |
Reversibility of FEV1 % | | |
Mean | 3.6±2.8 | 4.4±3.8 |
Range | 0.0–10.0 | 0.0–22.0¶ |
Mean±sem morning PEF L·min−1 | 461±13 | 436±13 |
Mean±sem evening PEF L·min−1 | 468±13 | 444±13 |
PEF variability | 5.4±3.2 | 5.5±3.8 |
Salbutamol puffs·day−1 | 0.44±0.86 | 0.94±0.14 |
BHR+ | 14/34 | 21/36 |
Atopy§ | 65/70 | 69/70 |
Rhinitis | | |
History of allergic rhinitis | 12 | 18 |
Actual use of nasal steroids | 13 | 20 |
Sputum eosinophils | | |
Score 0–1 (<5%) | 46 | 41 |
Score 2–4 (≥5%) | 8 | 11 |
Sputum ECP µg·L−1 | 714±1343 | 962±1654 |